机译:用奥拉帕布治疗BRCA突变癌症治疗患者的PARP抑制剂抗性和TP53突变:四个病例报告
UNICANCER Georges Francois Leclerc Canc Ctr Dept Biol &
Pathol Tumors Dept Oncol F-21079 Dijon;
UNICANCER Georges Francois Leclerc Canc Ctr Dept Biol &
Pathol Tumors Dept Oncol F-21079 Dijon;
UNICANCER Georges Francois Leclerc Canc Ctr Dept Biol &
Pathol Tumors Mol Biol Unit 1 Rue Prof;
UNICANCER Georges Francois Leclerc Canc Ctr Dept Biol &
Pathol Tumors Mol Biol Unit 1 Rue Prof;
Univ Bourgogne Franche Comte Ctr Rech F-21078 Dijon France;
UNICANCER Georges Francois Leclerc Canc Ctr Dept Biol &
Pathol Tumors Dept Oncol F-21079 Dijon;
UNICANCER Georges Francois Leclerc Canc Ctr Dept Biol &
Pathol Tumors Dept Oncol F-21079 Dijon;
UNICANCER Georges Francois Leclerc Canc Ctr Dept Biol &
Pathol Tumors Dept Oncol F-21079 Dijon;
UNICANCER Pathol Unit Dept Biol &
Pathol Tumors Georges Francois Leclerc Canc Ctr F-21079 Dijon;
UNICANCER Georges Francois Leclerc Canc Ctr Dept Biol &
Pathol Tumors Mol Biol Unit 1 Rue Prof;
resistance; PARP inhibitors; TP53; BRCA-mutated cancer; olaparib;
机译:FDA批准摘要:使用三行或更多行化学疗法治疗有害生殖系BRCA突变的晚期卵巢癌患者的Olaparib单药治疗
机译:FDA批准摘要:Olaparib单药治疗有害种系BRCA-突变的晚期卵巢癌治疗,用三种或更多种化疗进行治疗
机译:Rad51焦点作为种系BRCA突变乳腺癌同源重组修复和PARP抑制剂抗性的官能生物标志物
机译:接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
机译:甲酰胺糖基化和携带畸形TP53突变的癌细胞中的耐药性
机译:RAD51基因位点是种系BRCA突变乳腺癌中同源重组修复和PARP抑制剂抗性的功能性生物标志物
机译:铂类敏感性复发性浆液性卵巢癌患者的Olaparib维持治疗和BRCa突变:进展后paRp抑制剂治疗的总生存期调整
机译:在BRCa1缺陷癌症中paRp抑制剂抗性的新机制。